# Efficacy and Safety of Sirolimus in Children and Adolescents With Juvenile Nasopharyngeal Angiofibroma (JNA)

> **NCT05549167** · PHASE3 · RECRUITING · sponsor: **Federal Research Institute of Pediatric Hematology, Oncology and Immunology** · enrollment: 117 (estimated)

## Conditions studied

- Juvenile Nasopharyngeal Angiofibroma

## Interventions

- **DRUG:** Sirolimus

## Key facts

- **NCT ID:** NCT05549167
- **Lead sponsor:** Federal Research Institute of Pediatric Hematology, Oncology and Immunology
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-05-30
- **Primary completion:** 2029-09-30
- **Final completion:** 2029-12-30
- **Target enrollment:** 117 (ESTIMATED)
- **Last updated:** 2022-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05549167

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05549167, "Efficacy and Safety of Sirolimus in Children and Adolescents With Juvenile Nasopharyngeal Angiofibroma (JNA)". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT05549167. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*